Начало › Рак на белия дроб с недребноклетъчен тип › Мичиган › Detroit
Клинични проучвания за Рак на белия дроб с недребноклетъчен тип в Detroit, MI
44 проучвания за Рак на белия дроб с недребноклетъчен тип търсят участници в обекти в и около Detroit (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Набиране на участнициФаза 1/2
- Henry Ford Hospital - Detroit /ID# 271642, Detroit
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Набиране на участнициФаза 3
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 1/2
- Research Site, Detroit
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Набиране на участнициФаза 1
- Exelixis Clinical Site #65, Detroit
- Exelixis Clinical Site #13, Detroit
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Набиране на участнициФаза 3
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Набиране на участнициФаза 3
- Karmanos Cancer Institute, Detroit
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Набиране на участнициФаза 3
- Karmanos Cancer Institute, Detroit
- Henry Ford Health, Detroit
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Набиране на участнициФаза 2
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Набиране на участнициФаза 3
- Karmanos Cancer Institute, Detroit
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Набиране на участнициФаза 3
- Local Institution - 0293, Detroit
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Набиране на участнициФаза 1/2
- Barbara Ann Karmanos Cancer Center, Detroit
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 3
- Research Site, Detroit
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Набиране на участнициФаза 2
- Karmanos Cancer Institute, Detroit
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Набиране на участнициФаза 3
- Clinical Study Site, Detroit
- Clinical Study Sites, Detroit
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Набиране на участнициФаза 1
- Henry Ford Cancer Institute, Detroit
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Набиране на участнициФаза 3
- Research Site, Detroit
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Набиране на участнициФаза 1
- Henry Ford Cancer - Detroit, Detroit
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Набиране на участнициФаза 1/2
- Brigitte Harris Cancer Pavilion BHCP, Detroit
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Набиране на участнициФаза 3
- Henry Ford Cancer Institute, Detroit
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Набиране на участнициФаза 3
- Research Site, Detroit
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Набиране на участнициФаза 1
- Barbara Ann Karmanos Cancer Institute, Detroit
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Набиране на участнициФаза 3
- Wayne State University/Karmanos Cancer Institute, Detroit
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- Karmanos Cancer Institute, Detroit
A Study of DM005 in Patients With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- Henry Ford Cancer Institute, Detroit
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 1/2
- Henry Ford Health System, Detroit
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Набиране на участнициФаза 1/2
- Henry Ford Health, Detroit
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Набиране на участнициФаза 1/2
- Karmanos Cancer Institute, Detroit
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Набиране на участнициФаза 1/2
- Henry Ford Cancer Institute, Detroit
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Набиране на участнициФаза 1
- Karmanos Cancer Institute, Detroit
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Набиране на участнициФаза 1/2
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Набиране на участнициФаза 2
- Karmanos Cancer Institute, Detroit
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Набиране на участнициФаза 1
- Karmanos Cancer Institute, Detroit
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Набиране на участнициФаза 1
- Henry Ford Health System, Detroit
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Henry Ford Hospital, Detroit
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Набиране на участнициФаза 3
- Research Site, Detroit
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Henry Ford Hospital, Detroit
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- Henry Ford Health System, Detroit
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Набиране на участнициФаза 1/2
- Karmanos Cancer Institute, Detroit
First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy
Набиране на участнициФаза 1
- Karmanos Cancer Institute, Detroit
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Набиране на участнициФаза 1
- Henry Ford Cancer Institute, Detroit
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- Research Site 129, Detroit
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Набиране на участнициФаза 1/2
- Henry Ford Health, Detroit
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
Набиране на участнициФаза 2
- Karmanos Cancer Institute, Detroit
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Набиране на участнициФаза 1/2
- Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit
Проучвания за Рак на белия дроб с недребноклетъчен тип в други градове
- Houston, TX145 проучвания
- New York City, NY121 проучвания
- Arlington, VA104 проучвания
- Nashville, TN97 проучвания
- Boston, MA90 проучвания
- Los Angeles, CA87 проучвания
- St. Louis, MO73 проучвания
- Chicago, IL61 проучвания
- Baltimore, MD60 проучвания
- San Antonio, TX59 проучвания
- Columbus, OH57 проучвания
- Washington, DC55 проучвания
Други проучвания в Detroit
- Рак на гърдата33 проучвания
- Рак (всички видове)29 проучвания
- Колоректален рак26 проучвания
- Рак на яйчниците26 проучвания
- Метастатичен рак24 проучвания
- Рак на простатата22 проучвания
- Ендометриален рак21 проучвания
- Рак на белия дроб20 проучвания
- Множествен миелом19 проучвания
- Рак на стомаха16 проучвания
- Плоскоклетъчен карцином на главата и шията15 проучвания
- Остра миелоидна левкемия14 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.